3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
26
Myelodysplastic Syndromes
13
Recurrence
4
Leukemia, Myelomonocytic, Chronic
4
Lymphoma, Large B-Cell, Diffuse
3
Leukemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma
2
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myeloid Malignancies
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphodepleting Chemotherapy
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Biphenotypic, Acute
1
Hypomethylating Agent
1
Human Papillomavirus-Negative Neck Squamous Cell Carcinoma
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Congenital Bone Marrow Failure Syndromes
1
Burkitt Lymphoma
1
Anemia, Refractory, with Excess of Blasts
1
Accelerated Phase Myeloproliferative Neoplasm
1
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Congenital Bone Marrow Failure Syndromes
×
Decitabine
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled